Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

September saw several notable 'firsts' in the regulatory landscape alongside the approval of four novel drugs in the U.S. Among ...

One upcoming decision—on a perioperative PD-1 regimen for lung cancer—comes as the FDA considers an overhaul of trial designs in this treatment setting.

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Findings from the CheckMate 067 of patients with advanced melanoma include the longest follow-up of a checkpoint inhibitor in any tumor type.

Nivolumab, an immune checkpoint inhibitor lauded for its groundbreaking approach to cancer treatment, marked its 10th ...

It is the first of a slew of cancer drugs to now funded by Pharmac following the agency's multi-million dollar budget boost.

An FDA expert panel on Thursday voted against a broader use of Merck (MRK) and Bristol-Myers (BMY) immune checkpoint inhibitors Keytruda and Opdivo. Read more here.

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...